Reviewing the Approval Process of Teclistamab in Multiple Myeloma

Publication
Article
ONCOLOGY® CompanionONCOLOGY® Companion, Volume 38, Supplement 1
Volume 38
Issue 1
Pages: 10

A group of experts discussed the approval process for teclistamab use in patients with multiple myeloma.

During a recent Training Academy hosted by CancerNetwork, experts discussed insurance coverage during treatment with teclistamab-cqyv (Tecvayli) and the resulting adverse effects for patients with multiple myeloma.

The expert panel

The expert panel

Cesar Rodriguez Valdes, MD, on Inpatient Treatments

If we are to start a patient with the step-up [dosing] in the hospital, we get the approval and the hospital [absorbs the] costs of the teclistamab and the tocilizumab [Actemra] and whatever agents are required during the hospital stay. Then we don’t need to worry about how much of a financial burden it’s going to be for the patient, because it’s [simply] a package that the insurance is going to pay the hospital.

Kirollos Hanna, PharmD, BCPS, BCOP, FACC, on Outpatient Treatments

There is some burden on the patient, and we [do talk] to the insurance providers about whether they will cover the hotel stay if [patients are] from out of town…. It’s a daily clinic visit, so there’s usually a co-pay associated with that. There are labs drawn every day, so there’s usually something associated with that. We haven’t done a complete analysis yet from a patient perspective. What we’ve shown is that it reduces the cost of care because, at least from the clinic’s perspective, our cost of doing the work in the clinic is less than the cost of an extended stay in the hospital.

Scott Soefje, PharmD, MBA, BCOP, FCCP, on the Outpatient to Inpatient Process

We try to send them through the fast track. If it comes through remote monitoring, then there’s a way to get them directly admitted to the bed should they need it. We’ve had times where they told them, “Go to the [emergency department]” because they didn’t have a bed, and we had to get them stabilized and then find the bed to put them in.

Frances Bell, NP, on Insurance and Adverse Effect Management

Typically along with the approval for teclistamab, we’re also putting in for insurance authorization and approval for intravenous immunoglobulin [IVIG] for infection prophylaxis. Usually, [infection] starts within the second cycle or by the second cycle with teclistamab. If it’s not approved, we may need to do a peer-to-peer [review] to get it approved. With all of the B-cell maturation antigen agents, IVIG is used to prevent infection and is important.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
Related Content